vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Presurance Holdings, Inc. (PRHI). Click either name above to swap in a different company.
Arcellx, Inc. is the larger business by last-quarter revenue ($8.1M vs $5.7M, roughly 1.4× Presurance Holdings, Inc.). Presurance Holdings, Inc. runs the higher net margin — -369.2% vs -766.0%, a 396.9% gap on every dollar of revenue. On growth, Presurance Holdings, Inc. posted the faster year-over-year revenue change (-61.4% vs -79.3%). Over the past eight quarters, Arcellx, Inc.'s revenue compounded faster (-24.6% CAGR vs -44.7%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
ACLX vs PRHI — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $5.7M |
| Net Profit | $-62.3M | $-17.0M |
| Gross Margin | — | — |
| Operating Margin | -847.6% | -322.7% |
| Net Margin | -766.0% | -369.2% |
| Revenue YoY | -79.3% | -61.4% |
| Net Profit YoY | -765.1% | 32.9% |
| EPS (diluted) | $-1.13 | $-1.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.7M | ||
| Q3 25 | — | $6.8M | ||
| Q2 25 | — | $16.1M | ||
| Q1 25 | $8.1M | $15.9M | ||
| Q4 24 | $15.3M | $14.7M | ||
| Q3 24 | $26.0M | $16.0M | ||
| Q2 24 | $27.4M | $17.9M | ||
| Q1 24 | $39.3M | $18.6M |
| Q4 25 | — | $-17.0M | ||
| Q3 25 | — | $-4.0M | ||
| Q2 25 | — | $2.1M | ||
| Q1 25 | $-62.3M | $522.0K | ||
| Q4 24 | $-47.1M | $-25.4M | ||
| Q3 24 | $-25.9M | $52.8M | ||
| Q2 24 | $-27.2M | $-4.0M | ||
| Q1 24 | $-7.2M | $74.0K |
| Q4 25 | — | -322.7% | ||
| Q3 25 | — | -42.7% | ||
| Q2 25 | — | -22.6% | ||
| Q1 25 | -847.6% | -27.9% | ||
| Q4 24 | -348.2% | -177.1% | ||
| Q3 24 | -129.1% | -45.8% | ||
| Q2 24 | -127.8% | -24.3% | ||
| Q1 24 | -40.3% | 2.7% |
| Q4 25 | — | -369.2% | ||
| Q3 25 | — | -58.2% | ||
| Q2 25 | — | 12.7% | ||
| Q1 25 | -766.0% | 3.3% | ||
| Q4 24 | -308.4% | -172.4% | ||
| Q3 24 | -99.4% | 329.6% | ||
| Q2 24 | -99.3% | -22.1% | ||
| Q1 24 | -18.3% | 0.4% |
| Q4 25 | — | $-1.40 | ||
| Q3 25 | — | $-0.32 | ||
| Q2 25 | — | $0.17 | ||
| Q1 25 | $-1.13 | $0.04 | ||
| Q4 24 | $-0.87 | $-2.08 | ||
| Q3 24 | $-0.48 | $4.32 | ||
| Q2 24 | $-0.51 | $-0.32 | ||
| Q1 24 | $-0.14 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $52.1M |
| Total DebtLower is stronger | — | $12.2M |
| Stockholders' EquityBook value | $416.9M | $9.0M |
| Total Assets | $648.1M | $239.3M |
| Debt / EquityLower = less leverage | — | 1.36× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $52.1M | ||
| Q3 25 | — | $62.3M | ||
| Q2 25 | — | $58.3M | ||
| Q1 25 | $543.3M | $52.3M | ||
| Q4 24 | $587.4M | $48.8M | ||
| Q3 24 | $574.3M | $53.6M | ||
| Q2 24 | $516.7M | $33.0M | ||
| Q1 24 | $573.9M | $41.0M |
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | $12.1M | ||
| Q2 25 | — | $12.1M | ||
| Q1 25 | — | $12.0M | ||
| Q4 24 | — | $11.9M | ||
| Q3 24 | — | $16.5M | ||
| Q2 24 | — | $24.8M | ||
| Q1 24 | — | $24.9M |
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | $25.3M | ||
| Q2 25 | — | $28.2M | ||
| Q1 25 | $416.9M | $25.6M | ||
| Q4 24 | $454.8M | $21.5M | ||
| Q3 24 | $483.0M | $49.1M | ||
| Q2 24 | $487.2M | $-1.2M | ||
| Q1 24 | $496.6M | $2.6M |
| Q4 25 | — | $239.3M | ||
| Q3 25 | — | $285.0M | ||
| Q2 25 | — | $283.3M | ||
| Q1 25 | $648.1M | $277.1M | ||
| Q4 24 | $711.3M | $281.7M | ||
| Q3 24 | $764.9M | $299.9M | ||
| Q2 24 | $734.3M | $292.9M | ||
| Q1 24 | $779.7M | $301.1M |
| Q4 25 | — | 1.36× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.34× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 9.75× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $-43.9M |
| Free Cash FlowOCF − Capex | $-63.9M | — |
| FCF MarginFCF / Revenue | -786.4% | — |
| Capex IntensityCapex / Revenue | 9.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-43.9M | ||
| Q3 25 | — | $-681.0K | ||
| Q2 25 | — | $-2.8M | ||
| Q1 25 | $-63.1M | $-15.3M | ||
| Q4 24 | $-46.0M | $-32.7M | ||
| Q3 24 | $30.7M | $-10.7M | ||
| Q2 24 | $-36.2M | $-10.1M | ||
| Q1 24 | $-31.9M | $8.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-63.9M | — | ||
| Q4 24 | $-47.5M | — | ||
| Q3 24 | $28.4M | — | ||
| Q2 24 | $-39.5M | — | ||
| Q1 24 | $-38.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -786.4% | — | ||
| Q4 24 | -311.3% | — | ||
| Q3 24 | 109.2% | — | ||
| Q2 24 | -144.1% | — | ||
| Q1 24 | -97.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 8.8% | — | ||
| Q2 24 | 11.7% | — | ||
| Q1 24 | 16.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.34× | ||
| Q1 25 | — | -29.23× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.20× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 110.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
